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glaucoma visited practitioners more often (+0.74 / year),
had more exams (0.42), and were more likely to be using
drug combinations (+28.5%) and to be hospitalised
(+16.2%). Drugs represented the bulk of the expenses 
followed by exams and ofﬁce visits. Two main clinical
factors contributed to costs: abnormalities of the papilla
due to the presence of glaucoma (+ EURO 96.43) and the
number of treatment switches (+ EURO 127.62 / switch).
These were followed by IOP (+ EURO 7.08 / mmHg) and
VA (+ EURO 41.37 / 2 Lines lost VA). In comparison to
work conducted in the mid-nineties, drug costs increased
while hospital costs decreased, although methodologies
were different. CONCLUSION: Two independent factors
explained the bulk of total cost variance: the presence of
glaucoma and therapy switches. They contributed inde-
pendently in an additive way to total cost. Under isotropic
hypotheses, effective early treatment strategies aimed at
postponing the effects of glaucoma and controlling IOP
are expected to be cost saving in the long-term.
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OBJECTIVE: To assess and to identify the key variables
of the life-long societal net value of glaucoma treatment.
METHODS: A Markov model was used to reproduce the
average discounted cost of glaucoma treatment over 40
years in France on a 47-year-old cohort (52% female).
Clinical states were ﬁrst to fourth line treatment, no treat-
ment, laser, surgery, blindness and death. All patients
started ﬁrst line, went successively to the next line after
failure. After each failure (and always after the fourth
line) patients could have either laser or surgery followed
by no treatment, or a new ﬁrst line treatment. Transition
probabilities and resource utilisation came from of a
cross-sectional study with 5 years retrospective data col-
lection for the glaucoma treatment, and from national
statistics. In-patient and out-patient direct medical costs
and indirect costs were estimated from a societal point 
of view. The discount rate was ﬁxed at 5%. Sensitivity
analyses and second order Monte-Carlo simulation were
performed. RESULTS: Life expectancy of this cohort was
32.5 years. Discounted total cost was €6,990 compared
to €14,133 without discounting. Patients spent 12.3 years
in ﬁrst line, 5.1 in second, 3.9 in third, and 3.2 in fourth,
and 5.7 without treatment. They had 1.1 laser treatments
and 1.2 surgeries on average. They were legally blind for
2.1 years on average. Increasing ﬁrst line treatment dura-
tion by 25% would reduce discounted total cost to
€6,709, or €13,368 without discounting. Patients would
stay 1.9 years more in ﬁrst line, 0.8 years less in second,
0.6 years less in third, 0.6 years less in fourth and 0.3
years less without treatment. The use of surgery and laser
would decrease by 10%. CONCLUSION: Increasing 
ﬁrst line glaucoma treatment duration is a cost saving
approach over life of a patient according to our model.
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OBJECTIVES: In order to conduct a multi-national 
retrospective chart review with the purposes of assessing
resource utilization and costs associated with disease pro-
gression in Europe, a glaucoma staging system (GSS) was
needed. To date no universally accepted GSS exists, par-
ticularly one that takes into account economic consider-
ations. We developed and tested a modiﬁed system to
allow for unambiguous stage assignment of patients expe-
riencing varied severity of disease. METHODS: A review
of currently developed GSSs was conducted and the
Bascom Palmer GSS was selected as most adaptable for
economic analyses. A modiﬁed-Delphi panel of physicians
specializing in glaucoma treatment suggested modiﬁca-
tions to the system, with the end goal of assessing the eco-
nomic impact of treating glaucoma. Three centers were
identiﬁed in each of the four participating countries:
France, Germany, Italy and U.K. Approximately 12
charts per center were selected based on the inclusion/
exclusion criteria described in the study protocol. The
revised GSS was applied on all identiﬁed charts to clas-
sify patients by disease severity. Clinical and demographic
data were obtained from the charts and national-level
ﬁnancial data were obtained from health economists in
each country. RESULTS: The ﬁnal GSS comprises six
stages based principally on visual ﬁeld parameters. End-
stage disease deﬁnition was based on poor visual acuity
and inability to perform visual ﬁelds. The staging system
was able to classify over 100 identiﬁed charts of glaucoma
patients from normal to end-stage disease, and facilitated
resource utilization abstraction by individual stage.
CONCLUSIONS: An improved GSS to track progression
was designed which allows staging of patients from his-
torical chart data. This GSS may be used to monitor long-
term progression and is a useful tool for the purposes of
assessing the economic impact of glaucoma progression.
The tool should be tested prospectively to determine its
ultimate utility in clinical practice.
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